Anlon Healthcare Limited, founded in 2013, is a chemical manufacturing company specializing in high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These products serve as essential raw materials for manufacturing various pharmaceutical formulations, including tablets, capsules, and syrups, as well as ingredients for nutraceuticals, personal care, and animal health products. The company’s APIs adhere to stringent Indian and international pharmacopeia standards, such as IP, BP, EP, JP, and USP.

Anlon is one of the few Indian manufacturers of loxoprofen sodium dihydrate, an API widely used to treat pain and inflammation associated with conditions like rheumatoid arthritis and osteoarthritis. In addition to its core manufacturing, the company provides custom manufacturing services for complex chemical compounds, tailoring production to meet specific client requirements and achieve purity levels that often exceed industry standards. The company has secured Drug Master File (DMF) approvals from major global regulatory bodies, including ANVISA, NMPA, and PMDA, for its key products and has a portfolio of 65 commercialized products.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

• Robust Product Pipeline: The Company has a strong portfolio of 65 commercialized products, with 77 additional products in development and testing phases.
• Resilient Business Model: A scalable business model combined with a well-established customer base ensures stability and potential for future growth.
• High Barriers to Entry: The industry’s strict product standards and long customer approval cycles create high barriers to entry, protecting the company’s market position.
• Quality Assurance: The Company maintains rigorous quality control through in-house testing and dedicated quality assurance/quality control (QA/QC) teams.

The Company ANLON HEALTHCARE IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Funding capital expenditure requirements for Proposed Expansion (₹ 2 Cr.)
• Full or part repayment and/or prepayment of certain outstanding secured borrowings (term loan) availed by the Company (₹ 50 Cr.)
• Funding working capital requirements of the company (₹ 5 Cr.)

At the upper band of IPO ₹ 91, the stock is valued at 19.56 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.